Aspira Women’s Health (NASDAQ:AWH) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Aspira Women’s Health (NASDAQ:AWH) released its quarterly earnings results on Monday. The company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04, Yahoo Finance reports. The company had revenue of $2.42 million during the quarter, compared to analysts’ expectations of $2.60 million. During the same period in the prior year, the firm earned ($0.28) EPS.

Aspira Women’s Health Trading Up 0.9 %

AWH stock traded up $0.01 during midday trading on Tuesday, reaching $1.14. 10,465 shares of the company’s stock traded hands, compared to its average volume of 64,929. The stock’s 50-day moving average is $1.47 and its 200 day moving average is $2.84. The stock has a market cap of $16.28 million, a P/E ratio of -0.75 and a beta of 1.54. Aspira Women’s Health has a 52-week low of $0.86 and a 52-week high of $6.75.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on Aspira Women’s Health in a research report on Tuesday, July 2nd. They set a “sell” rating on the stock.

Aspira Women’s Health Company Profile

Aspira Women's Health Inc, together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States. The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.